Evoke is the only FDA-approved therapy with 24-month follow-up from a clinical study, according to a news release. A full commercial release is scheduled for 2023.
Evoke uses closed-loop technology and is designedto treat trunk and/or limb pain. The device earned FDA approval in March.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.